Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | CTRC | Q99895 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18389420 | 0.87 | L3MBTL1 (0.48) | CNR1ADORA3CTRCACACBACACA | |
| SCHEMBL20130841 | 0.87 | ADORA3 (0.42) | CNR1ADORA3CTRCACACBACACA | |
| SCHEMBL20130838 | 0.86 | ADORA3 (0.41) | CNR1ADORA3CTRCACACBACACA | |
| SCHEMBL18389604 | 0.85 | CNR1 (0.49) | CNR1ADORA3CTRCHSD11B1ALPL | |
| SCHEMBL18389332 | 0.85 | CNR1 (0.49) | CNR1ADORA3CTRCHSD11B1ALPL | |
| SCHEMBL20130794 | 0.85 | ACACB (0.45) | CNR1ADORA3CTRCHSD11B1ACACB | |
| SCHEMBL18389378 | 0.84 | ADORA3 (0.50) | ADORA3ACACBACACASCN9A | |
| SCHEMBL18794937 | 0.80 | CNR1 (0.42) | CNR1ADORA3CTRCHSD11B1ALPL | |
| SCHEMBL18389336 | 0.79 | CNR1 (0.44) | CNR1ADORA3CTRCHSD11B1 | |
| SCHEMBL19207323 | 0.78 | CNR1 (0.48) | CNR1ADORA3CTRCHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322699-B1 | 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-20180125823-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2017009274-A1 | 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125823-A1 | IMIDAZOLE DERIVATIVES | OXTR, DRD3, MC3R | CNR1 178/4885ADORA3 316/4885CTRC 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.